MktsMarkets

Alaunos Therapeutics, Inc.
NASDAQ: TCRTKey statistics
TCRT News
Stories mentioning TCRT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 3.00 | 0.00 | 0.00 | 2.00 | 5.00 | 0.00 | 4.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 427.00 | 362.00 | 469.00 | 185.00 | 347.00 | (87.00) | 143.00 | 180.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 1,012 | 910.00 | 1,187 | 1,039 | 1,094 | 759.00 | 1,150 | 1,170 |
| Operating Income (Loss) | (1,012) | (907.00) | (1,187) | (1,039) | (1,092) | (754.00) | (1,150) | (1,166) |
| Interest Income | ||||||||
| Interest Expense | 0.00 | |||||||
| Other Expense | 6.00 | 14.00 | 28.00 | 19.00 | 19.00 | 13.00 | 23.00 | 37.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (1,006) | (893.00) | (1,159) | (1,051) | (1,073) | (741.00) | (1,127) | (1,129) |
| Earnings Per Share (Basic) | (0.59) | (0.46) | (0.55) | (0.63) | (0.67) | (0.46) | (0.70) | (0.71) |
| Earnings Per Share (Diluted) | (0.59) | (0.46) | (0.55) | (0.63) | (0.67) | (0.46) | (0.70) | (0.71) |
| Weighted Average Shares Outstanding (Basic) | 1,948 | 1,948 | 2,183 | 1,676 | 1,601 | 1,601 | 1,601 | 1,600 |
| Weighted Average Shares Outstanding (Diluted) | 1,948 | 1,948 | 2,183 | 1,676 | 1,601 | 1,601 | 1,601 | 1,600 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TCRT
Alaunos Therapeutics, Inc. (NASDAQ: TCRT) is a stock listed on the Nasdaq Stock Market under the ticker symbol TCRT. It last traded at $1.60 (Nov 16, 2026, 4:00 PM ET), down 1.8% on the day. That gives Alaunos Therapeutics a market capitalisation of $6.9M.
Over the past 52 weeks TCRT has traded between $0.7200 and $4.50.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $1.0M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $0 | -$1.0M | — |
| Dec 31, 2025 | $3.0K | -$893.0K | -29766.7% |
| Sep 30, 2025 | $0 | -$1.2M | — |
| Jun 30, 2025 | $0 | -$1.1M | — |
From Alaunos Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…